 |
Prospector
Profile
07.1176
|
| |
| Larrea Biosciences Corporation |
NAICS |
325411 |
| 1628 Marshall
Houston, TX 77006 |
Description |
Vitamin Supplements Mfg. |
| (832) 695-0096 |
Employees |
1 |
|
Revenue |
(mil) |
0.3450 |
| |
Income |
(mil) |
-0.9100 |
| |
Assets |
(mil) |
0.0180 |
| |
Liability |
(mil) |
1.0710 |
| |
(for the year ended 2007-04-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
R.E. Bassie & Company raised doubts on the ability of Larrea Biosciences Corporation to continue as a going concern due to its working capital deficiency of $1,067,597 at April 30, 2007. The Company is currently seeking additional funds through future debt or equity financing to offset future cash flow deficiencies.
|
| |
|
Intellectual Property:
The Company, through its Global Botanics, Inc. subsidiary, owns U.S. Patents 5,837,252; 5,945,106; 6,004,559 and 6,039,955. These patents relate to the production and use of proprietary extracts from the North American plant species, Larrea tridentata. The current patented technology broadly covers extraction and purification technologies as well as utility of extracts as antiviral, anti-inflammatory, antimicrobial and antioxidant agents. Specific claims allowed in the issued patents include: a method of treating herpes lesions and herpes viruses in humans using an effective amount of an extract of Larrea tridentata; a method of treating herpes viruses and symptomatic herpes virus lesions of the group: herpes simplex 1 (cold sores), herpes simplex 2 (genital herpes), varicella-zoster virus (chickenpox and shingles), human herpes virus 4 (Epstein-Barr virus, mononucleosis), human herpes virus 5 (cytomegalovirus), human herpes viruses 6 and 7 (roseoloviruses), and herpes virus 8 (Kaposi's sarcoma); stimulation of human immune system function; a herpes treatment agent comprising a formulation of Larrea tridentata; and an agent for treatment of inflammation and inflammatory disease comprising a formulation of Larrea tridentata. In addition to the existing patents, Larrea will aggressively prosecute pending patent applications to secure final issuance of multiple U.S. and international patents, which expand on the already patented technologies. [SEC Filing 10-KSB 08-06-07]
|
| |
|
Description:
The Company, through its wholly owned subsidiary, LarreaRx, Inc., engages in manufacturing, licensing, and distributing green dietary supplements.
|
| |
|
Officers:
Peter P. Smetek, Jr. (CEO, CFO & Dir.)
|
| |
|
Auditor:
R.E. Bassie & Company
|
| |
|
Securities:
Common Stock-Symbol LRRA.PK; Other OTC;
34,371,945 common shares outstanding as of April 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
